News

Competitive ERC Advanced Grant awarded to Bart Lambrecht to study the role of protein crystallization in asthma
6 April 2018
Bart Lambrecht (VIB-UGent Center for Inflammation Research) is awarded an Advanced Grant. To qualify, a scientist has to be able to prove exceptional leadership and a solid track record of significant research achievements over at least 10 years.
Trapping multidrug-resistant bacteria in molecular glue
28 February 2018
Researchers at VIB, KU Leuven and UZ Leuven devised a novel approach to develop antibacterial drugs. With antibiotic resistance on the rise worldwide, such new drugs are urgently needed.
Counteracting the effects of TNF receptor-1 has therapeutic potential in Alzheimer’s disease
22 February 2018
Alzheimer’s disease (AD) is the most common form of dementia and increasing evidence has shown that neuroinflammation is an important and early hallmark of the pathogenesis.
Protein IL-33 found to drive allergic sensitivity in the neonatal lung
20 January 2017
Scientists from the lab of Bart Lambrecht (VIB-UGent) and Erasmus University have found evidence that interleukin-33 (IL-33), a protein created by white blood cells, is a key driver of allergic sensitivity in the lungs of newborns.
Researchers unravel viruses’ strategies to dodge immune systems
7 November 2016
Researchers led by Savvas Savvides (VIB-UGent) gained surprising insights into how viruses use proteins to inactivate the immune systems of their hosts.
Researchers take a new step towards non-antibiotic bladder infection therapies
23 September 2016
A team of scientists has gained fresh insight into the development of bladder infections, also known as cystitis. These findings are the result of VIB-VUB researchers & their American colleagues at the center for Women’s Infectious Disease Research.
Positive Interim Phase 1 Data for DepoVax™-based Respiratory Syncytial Virus (RSV) Vaccine Candidate
6 July 2016
Immunovaccine Inc. announced that a team of investigators has completed an interim analysis of the safety and immunogenicity of its DepoVax™ prophylactic RSV-vaccine candidate (DPX-RSV) in a Phase 1 clinical trial in healthy older adult volunteers.
Research opens new treatment strategies for specific form of Psoriasis
25 April 2016
Psoriasis is a long-lasting autoimmune disease that is characterized by patches of abnormal and inflamed skin. It is generally thought to have a genetic origin, which can be further triggered by environmental factors.
The Baillet Latour grant 2016 for medical research awarded to Prof. Mohamed Lamkanfi
14 April 2016
To promote medical research in Belgium, the Baillet Latour Fund awards every year a Grant to help a young group leader. This year the Grant is awarded to Professor Mohamed Lamkanfi for his research project in the field of infectious diseases.
Decades-old mystery disease identified and potential cure found
30 March 2016
A mysterious inflammatory disease has been afflicting a Flemish family for three generations, causing severe skin lesions, fevers, pain and exhaustion. This disease, which previously had no known cause or cure, has now been identified as PAAND.
Raising a child has a bigger effect on the immune system than the flu vaccine or gastroenteritis
15 February 2016
Dr Adrian Liston, a researcher at VIB and KU Leuven who co-led the research said: "This is the first time anyone has looked at the immune profiles of two unrelated individuals in a close relationship.
Novel insights in the attachment of the bacterial carcinogen Helicobacter pylori
14 January 2016
This BabA protein proves to be a molecular chameleon that adapts it binding properties and preference for different ABO-blood group sugars according to their prevalence in different human populations.
A novel mechanism that helps activated dendritic cells to initiate effective immunity
18 December 2015
Phagocytosis represents a critical innate barrier against infection and serves the clearance of extracellular microbes, infected and dying cells. The results are published in the December issue of the prestigious journal Immunity.
Immunovaccine’s vaccine candidate for Respiratory Syncytial Virus is well tolerated in patients in Phase 1 clinical trial
30 October 2015
Immunovaccine Inc., a clinical stage vaccine and immunotherapy company, announced that safety data from a Phase 1 clinical study showed that its DepoVax™ prophylactic Respiratory Syncytial Virus vaccine candidate was well tolerated.
Disruption of brain-blood barrier might influence progression of Alzheimer’s
29 September 2015
The team of Roosmarijn Vandenbroucke in the Claude Libert Group (VIB/UGent) combined their knowledge and expertise related to inflammation with the expertise in Alzheimer’s disease present in the Bart De Strooper Group (VIB/KU Leuven).

Get news updates:

Email updates
Follow us on Twitter
Like us on Facebook
RSS